Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
H. Lundbeck A/S
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The participant has a diagnosis of migraine as defined by ICHD-3 guidelines confirmed at the Screening Visit.
The participant has a history of migraine onset ≥12 months prior to the Screening Visit.
The participant has ≥2 migraine days and headache occurring on \<15 days per month for each month within the past 3 months prior to the Screening Visit.
The participant has a body mass index (BMI) ≥18.5 and ≤ 35 kilograms per meter squared (kg/m\^2) at the Screening Visit.
You may not be if
The participant has previously been dosed with an anti-pituitary adenylate cyclase-activating peptide (PACAP) treatment.
The participant has participated in a clinical trial \<30 days prior to the Screening Visit.
The participant has taken any investigational medicinal product (IMP) \<3 months or \<5 half-lives of that product, whichever is longer, prior to Visit 1.
The participant is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not willing to use adequate contraceptive methods.
The participant has known or suspected hypersensitivity or intolerance to the IMP, auxiliary medicinal product (AxMP), or their excipients.
